CD8A and melanoma: It efficiently amplified a robust cytotoxic CD8+T cell and natural killer (NK) cell immunity in vivo, resulting in significant tumor regression and prolonged survival of the syngeneic B16‐OVA melanoma model in fully immunocompetent mice.